On July 16, QingSong Health rose 8.49% in regular trading, trading at HKD 7.74/share, with turnover of HKD 132 million.

The rally was driven by a convergence of recent positive developments. The company's core AI product MedClaw has passed the China Academy of Information and Communications Technology (CAICT) full 13-dimension certification, with three capabilities receiving the only full-score rating in the assessment, reinforcing its credibility in the medical AI space.

Supporting the upward momentum, the company has been actively executing its previously announced HKD 100 million share buyback program, having repurchased over 5 million shares to date. Controlling shareholder Yang Yin also voluntarily extended her lock-up period to early next year, signaling confidence in the company's trajectory. Additionally, QingSong Health recently announced strategic partnerships with Alibaba Cloud and Chinese Online to strengthen its AI infrastructure from both computing power and data dimensions, while launching the evidence-based medical recording device ZhengYin at the China Internet Conference.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)